ZabBio
ZabBio develops monoclonal antibody-based therapeutics targeting infectious diseases and reproductive health, with an emphasis on scalable, low-cost production for large markets. The company is developing a human contraceptive antibody formulated as a vaginal film (ZB-06); a Phase 1 clinical trial was completed in 2022 and a dose-finding Phase 2a was planned for 2024. The ZB-06 program is a collaborative, grant-funded project involving academic and industry partners.
Industries
health-care
manufacturing
medical
pharmaceutical
Nr. of Employees
small (1-50)
ZabBio
San Diego, California, United States, North America
Products
ZB-06 (human contraceptive antibody)
A human monoclonal antibody formulated as a vaginal film intended for on-demand female contraception. The antibody agglutinates sperm and traps sperm in cervical mucus to prevent ascent and fertilization.
ZB-06 (human contraceptive antibody)
A human monoclonal antibody formulated as a vaginal film intended for on-demand female contraception. The antibody agglutinates sperm and traps sperm in cervical mucus to prevent ascent and fertilization.
Expertise Areas
- Monoclonal antibody development
- Contraceptive product development
- Reproductive health therapeutics
- Early-phase clinical trials
- Regulatory submissions (IND)
- Formulation development (vaginal films)
- Academic-industry collaborative research
Key Technologies
- Monoclonal antibody therapeutics
- Vaginal film drug delivery
- Antibody-mediated agglutination mechanisms
- Clinical trial operations (Phase 1/2a)
- IND regulatory submission processes